Patent details

301295 Product Name: Baloxavir marboxil, of een farmaceutisch aanvaardbaar zout daarvan

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
301295
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP4219508
Status:
Application Pending
Application number:
301295
Procedural language:
Dutch
First Applicant Residence Country:
Japan (JP)

Marketing Authorization

Marketing Authorization Number:
EU/1/20/1500
Marketing Authorization Type:
EEA
Marketing Authorization Date:
08/01/2021
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
29/10/2024
First Marketing Authorization date:
08/01/2021
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
30/10/2024
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
29/10/2024
 
 

 

Name:
Shionogi & Co., Ltd
Address:
1-8, Doshomachi 3-chome Chuo-ku, 541-0045, Osaka-shi, Osaka, Japan (JP)

Agent

Name:
ir. F.A. Geurts c.s.
From:
29/10/2024
Address:
Octrooibureau Vriesendorp & Gaade B.V. Koninginnegracht 19, 2514 AB, Den Haag, Netherlands (NL)
To:

Publication

Bulletin

Bulletin Heading:
SPC
Journal edition number:
45/24
Publication date:
06/11/2024
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date Document type Document Description Number of pages File Type
18/02/2025 SPC Documents Accompanying letter SPC 2 PDF /8/7/5/5/5/0801055578/docs/301295_10_supplprotectioncertificate20250220124839848.pdf
16/02/2025 SPC Documents Accompanying letter SPC 2 PDF /8/7/5/5/5/0801055578/docs/301295_9_supplprotectioncertificate20250218092952181.pdf
18/11/2024 Outgoing Correspondence Letter to applicant 2 PDF /8/7/5/5/5/0801055578/docs/301295_8_631672l173.pdf
01/11/2024 Outgoing Correspondence Confirmation receipt request 2 PDF /8/7/5/5/5/0801055578/docs/301295_0_630057l174.pdf
29/10/2024 SPC Documents Annex SPC 2 PDF /8/7/5/5/5/0801055578/docs/301295_1_supplprotectioncertificate20241030015712450.pdf
29/10/2024 SPC Documents Accompanying letter SPC 2 PDF /8/7/5/5/5/0801055578/docs/301295_2_supplprotectioncertificate20241030020634700.pdf
29/10/2024 SPC Documents Annex SPC 1 PDF /8/7/5/5/5/0801055578/docs/301295_3_supplprotectioncertificate20241030020440929.pdf
29/10/2024 Application Form First filed application form 4 PDF /8/7/5/5/5/0801055578/docs/301295_4_applicationform20241030014518626.pdf
29/10/2024 SPC Documents Marketing Authorization SPC 3 PDF /8/7/5/5/5/0801055578/docs/301295_5_supplprotectioncertificate20241030015917463.pdf
29/10/2024 SPC Documents Annex SPC 2 PDF /8/7/5/5/5/0801055578/docs/301295_6_supplprotectioncertificate20241030015823618.pdf
29/10/2024 SPC Documents Summary of the characteristics of the product 13 PDF /8/7/5/5/5/0801055578/docs/301295_7_supplprotectioncertificate20241030020350236.pdf